ArticleThe Lancet. Microbe2026
Burden and genomic characterisation of Shigella-associated diarrhoea in children younger than 5 years in Lusaka, Zambia: a prospective cohort study.
Article in The Lancet. Microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fluoroquinolone resistance-associated determinants in ciprofloxacin-susceptibleFrontiers in microbiology · 2026Article
Corrections and comments
- Update of
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShigella is a leading cause of childhood diarrhoea in low-income and middle-income countries and is increasingly resistant to first-line antibiotics. We conducted a surveillance study to assess the incidence, genomic characteristics, and antimicrobial resistance (AMR) profiles of Shigella infections in children younger than 5 years with moderate-to-severe diarrhoea (MSD) in Lusaka, Zambia.
methodsBetween Sept 15, 2020, and Nov 30, 2021, a prospective cohort study was conducted, which included 1400 children younger than 5 years enrolled during a community census in a periurban setting and passively followed up for 9·5 months for MSD. During enrolment, sociodemographic data were collected using electronic questionnaires, whereas clinical data were collected through the DHIS platform. The main outcome, Shigella in diarrhoeal stool in children younger than 5 years, was detected using culture and loop-mediated isothermal amplification targeting the ipaH gene. Cox proportional hazards models were used to assess the incidence and risk factors of Shigella (ipaH) infections. Whole-genome sequencing was used to characterise the genomic diversity and AMR genes, complemented by phenotypic antibiotic susceptibility testing.
findings230 first episodes of Shigella were noted over a follow-up time of 9581·7 child-months, yielding an incidence of 24·0 (95% CI 21·1-27·3) cases per 1000 child-months, with the highest incidence among children aged 2-3 years. The key risk factors identified were the water source (p=0·025) and age group (p=0·014). Genotypic characterisation revealed ten Shigella flexneri, nine Shigella sonnei, and three Shigella boydii isolates. The S sonnei isolates formed two clusters, differing in virulence factors and plasmid profiles, indicating two possible circulating strains. Shigella isolates showed phenotypic and genotypic multidrug resistance (MDR), including against trimethoprim, aminoglycosides, and β-lactams. Plasmid-mediated quinolone resistance (qnrS1) was identified in four S flexneri isolates, with these genes located on the IncFIB(K) plasmid, highlighting the potential for horizontal transmission and spread of quinolone resistance in this region. No phenotypic and genotypic resistance to macrolides, the first-line treatment for Shigella infection in Zambia, was observed.
interpretationWe report a high burden of Shigella with MDR, including resistance to fluoroquinolones. These findings highlight the increasing resistance of Shigella to first-line antibiotics and underscore the importance of developing safe and effective vaccines, improving water, sanitation, and hygiene conditions, and ongoing AMR surveillance.
fundingThe EDCTP2 programme, supported by the EU, the Faculty for the Future Foundation, The Netherlands Organisation for Health Research and Development, and Health-Holland AMR-Global, Gloria, and Track-AMR.
Indexed as
Identifiers
42612653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.